(Q42169796)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Manfredi Rizzo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Jelena Vekic

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Spyridon Koulouris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Aleksandra Zeljkovic

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Zorana Jelic-Ivanovic

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Vesna Spasojevic-Kalimanovska

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Giovam Battista Rini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Dimitrios Sakellariou

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Socrates Pastromas

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Dimitri P Mikhailidis

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

12 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

584-590

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20462890%20AND%20SRC:MED&resulttype=core&format=json

Diabetic dyslipidaemia: from basic research to clinical practice.

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Lipids and lipoproteins in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Who needs to care about small, dense low-density lipoproteins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Metabolic origins and clinical significance of LDL heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Clinical relevance of postprandial lipaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Lipoprotein(a). A genetic risk factor for premature coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Lipoprotein(a) and ischemic cerebrovascular disease in young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

LDL concentration and particle size after treatment with rosiglitazone in patients with diabetes mellitus type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Smallest LDL particles are most strongly related to coronary disease progression in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

The clinical relevance of low-density-lipoproteins size modulation by statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319710366431